Immunogenicity and safety of the 9-valent HPV vaccine in men

Highlights • We evaluated 9-valent HPV vaccine immunogenicity and tolerability in men and women 16–26 years old. • GMTs for vaccine HPV types for HM were non-inferior to those of women at month 7. • Administration of 9vHPV vaccine to both 16–26 year old men and women was generally well tolerated....

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Vaccine 2015-11, Vol.33 (48), p.6892-6901
Hauptverfasser:	Castellsagué, X, Giuliano, A.R, Goldstone, S, Guevara, A, Mogensen, O, Palefsky, J.M, Group, T, Shields, C, Liu, K, Maansson, R, Luxembourg, A, Kaplan, S.S
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Allergy and Immunology Cancer Cervical cancer Female HPV Human papillomavirus Humans Immunization Immunization Schedule Immunogenicity Male Men Papillomavirus Papillomavirus Infections - prevention & control Papillomavirus Vaccines - administration & dosage Papillomavirus Vaccines - adverse effects Papillomavirus Vaccines - immunology Safety Treatment Outcome Vaccine Vaccines Womens health Young Adult Young adults
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • We evaluated 9-valent HPV vaccine immunogenicity and tolerability in men and women 16–26 years old. • GMTs for vaccine HPV types for HM were non-inferior to those of women at month 7. • Administration of 9vHPV vaccine to both 16–26 year old men and women was generally well tolerated.
ISSN:	0264-410X 1873-2518
DOI:	10.1016/j.vaccine.2015.06.088